Announcements Trials
Browse Landscape

Phase

Phase 2 174Phase 3 127Phase 1 54Phase 1/2 53Phase 2/3 14Phase NA 3Phase 4 3Phase EARLY_PHASE1 2

Status

Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Muscle Invasive Bladder Urothelial Carcinoma 1Breast Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 12pembrolizumab 9Biopsy 8Nivolumab 7Radiotherapy 6Specimen Handling 5Radiosurgery 4Cyclophosphamide 4fludarabine 3X-Rays 3Temozolomide 3Rituximab 3Paclitaxel 3Leukapheresis 3Dexamethasone 3Aspirin 3perflutren 2alovudine 2Vaccines 2Tirzepatide 2Surgical Procedures, Operative 2Positron-Emission Tomography 2Phantoms, Imaging 2Niacinamide 2Neoadjuvant Therapy 2Losartan 2Letrozole 2Ketoconazole 2Irinotecan 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Carboplatin × 90 days × Clear all
NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Brigham and Women's Hospital

Phase EARLY_PHASE1 Enrolling by invitation
18 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

NCT06637306 2026-05-14

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase EARLY_PHASE1 Recruiting
15 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡